Literature DB >> 7053242

Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics.

K Stoeckel, P J McNamara, R Brandt, H Plozza-Nottebrock, W H Ziegler.   

Abstract

The kinetics of ceftriaxone, a cephalosporin, was studied in six healthy subjects who received bolus injections of 150, 500, and 1,500 mg intravenously in a random crossover fashion. Although total drug concentration time profiles after all doses could be described by biexponential equation, simple compartment analysis was inappropriate because a disproportional increase in the area under the total drug concentration time curves occurred with dose. This resulted in a dose-dependent increase in total systemic clearance (ClTS) from 9.7 ml/min at the 150-mg dose to 13 ml/min at the 1500-mg dose. The dose-dependent changes in ClTS could be explained in terms of the concentration-dependent plasma protein binding of ceftriaxone (fplasma ranging from 0.04 to 0.167), because the area under the free drug concentration time curves (AUCFO-infinity) increased proportionately to dose. Mean total clearance with reference to free (unbound) ceftriaxone (ClFS) was constant at 255 ml/min. Calculated mean renal clearance with reference to free ceftriaxone (ClFR) was 173 ml/min, or slightly more than the average glomerular filtration rate in humans. Mean plasma ceftriaxone t1/2 was not influenced by dose and averaged 8 hr. This biological t1/2 is by far the longest ever for a cephalosporin in healthy subjects.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7053242     DOI: 10.1038/clpt.1981.90

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  82 in total

1.  Ceftriaxone and Cefotaxime Have Similar Effects on the Intestinal Microbiota in Human Volunteers Treated by Standard-Dose Regimens.

Authors:  Charles Burdet; Nathalie Grall; Morgane Linard; Antoine Bridier-Nahmias; Michèle Benhayoun; Khadija Bourabha; Mélanie Magnan; Olivier Clermont; Camille d'Humières; Olivier Tenaillon; Erick Denamur; Laurent Massias; Sarah Tubiana; Loubna Alavoine; Antoine Andremont; France Mentré; Xavier Duval
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

2.  Influence of plasma exchange pheresis on plasma elimination of ceftriaxone.

Authors:  J S Bakken; S J Cavalieri; D Gangeness
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Effect of protein binding on the pharmacological activity of highly bound antibiotics.

Authors:  Stephan Schmidt; Katharina Röck; Martina Sahre; Olaf Burkhardt; Martin Brunner; Maximilian T Lobmeyer; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2008-09-08       Impact factor: 5.191

4.  Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.

Authors:  J M Entenza; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

5.  Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis.

Authors:  Yanli Zhao; Merit E Cudkowicz; Jeremy M Shefner; Lisa Krivickas; William S David; Francine Vriesendorp; Alan Pestronk; James B Caress; Jonathan Katz; Ericka Simpson; Jeffrey Rosenfeld; Robert Pascuzzi; Jonathan Glass; Kourosh Rezania; Jerold S Harmatz; David Schoenfeld; David J Greenblatt
Journal:  J Clin Pharmacol       Date:  2014-05-16       Impact factor: 3.126

6.  Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment.

Authors:  I H Patel; J G Sugihara; R E Weinfeld; E G Wong; A W Siemsen; S J Berman
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

Review 7.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

8.  Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis.

Authors:  T Y Ti; L Fortin; J H Kreeft; D S East; R I Ogilvie; P J Somerville
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

9.  In vitro protein binding of cefonicid and cefuroxime in adult and neonatal sera.

Authors:  J M Benson; F D Boudinot; A T Pennell; F E Cunningham; J T DiPiro
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

10.  The clinical relevance of plasma protein binding changes.

Authors:  Jason A Roberts; Federico Pea; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.